A bill to provide for appropriate cost-sharing for insulin products covered under private health plans, and to establish a program to support health care providers and pharmacies in providing discounted insulin products to uninsured individuals.

Summary of Bill S. 4512 (119th Congress) — Insulin Cost-Sharing and Discount Program

Purpose and intent

• S. 4512 seeks to reduce the out-of-pocket cost burden for insulin for individuals with private health plans.
• The bill also aims to create a program to assist health care providers and pharmacies in offering discounted insulin products to uninsured individuals.
• Broadly, it addresses affordability of insulin and access for uninsured populations by establishing cost-sharing provisions and an accompanying support program.

Key provisions and changes

1. Cost-sharing framework for privately insured individuals

   • The bill proposes rules to structure or limit cost-sharing obligations (e.g., copays, coinsurance, or deductibles) for insulin products covered under private health plans.
   • The framework is designed to ensure insulin affordability within private market coverage, potentially reducing patient liability at the point of sale.

2. Program to assist uninsured individuals

   • Establishment of a dedicated program to support the provision of discounted insulin to uninsured people.
   • The program would involve coordination among health care providers and pharmacies to facilitate access to discounted insulin for those without private insurance.
   • The specifics likely include eligibility criteria, dispensing mechanisms, and processes to qualify for discounts.

3. Support for providers and pharmacies

   • The legislation contemplates targeted support or incentives for healthcare providers and pharmacies participating in the program.
   • This could encompass reimbursement structures, administrative assistance, or other resources to implement discounted insulin distribution to uninsured patients.

Who would be affected

• Individuals with private health plans: Expected changes to insulin cost-sharing obligations, potentially lowering out-of-pocket costs for covered insulin products.
• Uninsured individuals: Improved access to discounted insulin through the new program.
• Health care providers and pharmacies: Entities that would participate in delivering discounted insulin to uninsured patients and may receive program-related support.

Procedural and timeline aspects

• Introductory status: Introduced in the Senate and referred to the Committee on Health, Education, Labor, and Pensions (HELP) on May 13, 2026.
• Sponsor: Co-sponsor John Neely Kennedy.
• Next steps in process: Pending committee consideration, markups, and potential floor action. The timeline depends on committee movement and Senate proceedings.

Potential impact and considerations

• Could lower patient costs for insulin under private plans, addressing affordability barriers.
• Aims to expand access for uninsured individuals through an organized discount program, potentially reducing financial obstacles to obtaining insulin.
• Implementation details (eligibility, discount levels, administration, funding) will shape the effectiveness and reach of the program.
• Fiscal considerations (program funding, sustainability) and administration (verification, fraud prevention) will be important during committee deliberations.

Note: This summary reflects the publicly available information on the bill’s title, stated purpose, and introductory actions. Specific statutory text, funding levels, discount rates, eligibility criteria, and administrative mechanisms would be defined in the bill’s language as it advances through amendments and committee consideration.